A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.

Simon J CrabbSyed HussainEileen Soulis Samantha HinsleyLaura DempseyAvril TrevethanYeePei SongJim BarberJohn FrewJoanna Gale Guy FaustSusannah BrockUrsula McGovernOmi ParikhDeborah EntingSanthanam SundarGihan RatnayakeKathryn LeesAlison Jane Birtle Thomas Powles Robert J Jones

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Maintenance rucaparib, following platinum-based chemotherapy, extended PFS in DRD biomarker-selected patients with mUC and was tolerable. Further investigation of poly ADP-ribose polymerase inhibition in selected patients with mUC is warranted.

Keyphrases

phase ii
clinical trial
double blind
open label
placebo controlled
phase iii
locally advanced
small cell lung cancer
study protocol
radiation therapy
randomized controlled trial